Clinical AI company Sensyne Health has signed a five-year non-exclusive strategic research agreement (SRA) with Milton Keynes University Hospital NHS Foundation Trust.
The agreement will see Sensyne’s AI technology applied to anonymised patient data for research into new medicines. This brings the combined total of anonymised data available for analysis by Sensyne to 4.5 million patients.
This is the latest in a string of strategic research agreements Sensyne has entered with NHS trusts, including Oxford University Hospitals NHS Foundation Trust, Chelsea & Westminster Hospitals NHS Foundation Trust, South Warwickshire NHS Foundation Trust, Wye Valley and George Eliot NHS trusts.
The AI company has also entered an agreement with pharmaceutical company Bristol Myers Squibb to apply its machine learning to conduct research into disease progression.
This is Sensyne’s fourth partnership with a major pharmaceutical company following collaborations with Bayer, Roche and Alexion.
The London-listed company reported revenue of £2.1m for the year ended 30 April 2020 against £0.1m in 2019.
Paul Drayson, CEO of Sensyne Health, said: ‘SRAs are a fundamental part of Sensyne’s unique model – giving NHS trusts equity, funding and the ability to share in revenues.
‘Growing our access to anonymised patient data is key to our strategy. This new non-exclusive SRA moves us closer to our target of over 5 million unique patient records in the current financial year.’